Opaleye Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Opaleye Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-28,400	Closed	-$1.65M	–	44
2017 Q3	$1.65M	Buy	+28,400	New	+$3.06M	0.58%	31
2014 Q1	–	Sell	-56,900	Closed	-$3.64M	–	31
2013 Q4	$3.64M	Buy	+56,900	New	+$3.29M	2.86%	12

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Opaleye Management's ICPT Position: Q4 2017 in Review

Opaleye Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2017, closing a stake of 28,400 shares — an estimated $1.65M sold.

Opaleye Management first reported a position in ICPT in Q4 2013 and held it in 2 quarters. The position peaked at $3.64M in Q4 2013. 169 funds tracked by Wall St. Rank hold ICPT as of Q4 2017.

Opaleye Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Opaleye Management sold 28,400 Intercept Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.65M.
Opaleye Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 2 quarters.
Opaleye Management's Intercept Pharmaceuticals, Inc. position peaked at $3.64M in Q4 2013.
169 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2017.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.